6/ Caveats worth saying out loud: • Lynx Dx (test manufacturer) funded portions; some authors are employees • External validation cohort, not yet RCT • Performance was consistent across Black and non-Black patients — important https://t.co/hgfteskLOU PMI…
NEW in J Urol: urine test (MPS2-AS) beats mpMRI for AS upgrade prediction. n=330, 11 sites: · AUC 0.82 vs 0.73 (GG≥3) · Avoids 64% biopsies, misses 3% upgrades · MRI alone missed 18% · Lynx Dx funded (disclosed) https://t.co/hgfteskLOU
Non-Invasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI https://t.co/zbrUdvg06x
3️⃣ MPS2 liquid biomarker utility in active surveillance Emerging JUrology in-press data suggest MPS2 may improve NPV for upgrading versus mpMRI and could offer a lower-cost approach to risk stratification in the active surveillance setting. https://t.co…